Article

Circulating Tau Profiles in Pediatric and Adult Patients with Spinal Muscular Atrophy

2025-12-29

Abstract excerpt

<h4>Objective</h4> To determine alterations in circulating Tau and phosphorylated Tau (pTau) profiles in pediatric and adult patients with spinal muscular atrophy (SMA). <h4>Methods</h4> Circulating total Tau, pTau-181, pTau-217, pTau-262, and pTau-396 concentrations were measured across three cohorts: 1) adults including healthy controls, SMA patients, and ALS patients; 2) pediatric SMA patients and age-matched...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 44a30232-def7-5e26-a084-f058cc5097c5
DOI: 10.64898/2025.12.19.25342711

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circulating Tau Profiles in Pediatric and Adult Patients with Spinal Muscular AtrophyDOI 10.64898/2025.12.19.25342711Read

Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular AtrophySemantic proximity Read

Neuronal Pentraxin 2 as a Potential Biomarker for Nusinersen Therapy Response in Adults with Spinal Muscular Atrophy: A Pilot StudySemantic proximity Read

Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatmentSemantic proximity Read

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.Semantic proximity Read

Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study.Semantic proximity Read

Nusinersen rescues taurine deficiency in severe Spinal Muscular AtrophySemantic proximity Read

System-Wide Proteomic Remodeling in Spinal Muscular Atrophy Reveals Tissue-Specific Responses and Partial Rescue by SMN RestorationSemantic proximity Read

Targeted brain-specific tauopathy compromises peripheral skeletal muscle integrity and functionSemantic proximity Read

Safety and Efficacy of Vesemnogene Lantuparvovec, an AAV-Based Gene Therapy in Young Children Under 24 Months with Spinal Muscular Atrophy in Low- and Middle-Income Countries. Second Interim Report (August 2025)Semantic proximity Read

Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical StudySemantic proximity Read

Twelve-Month Outcomes of Intrathecal Vesemnogene Lantuparvovec for Spinal Muscular Atrophy in Children Younger than 24 Months in Low- and Middle-Income CountriesSemantic proximity Read

Multiple System Atrophy: Pathology, Pathogenesis, and Path ForwardSemantic proximity Read